金吾财讯 | 再鼎医药(09688)公布截至2024年9月30日止三个月及九个月业绩。第三季，亏损净额4167.1万元(美元，下同)，同比收窄39.74%。每股基本亏损0.04元。期内总收入1.02亿美元，同比增长47.72%。前三季，亏损净额1.75亿元，同比收窄26.66%。每股基本亏损0.18元。期内总收入2.9亿元，同比44.32%。2024年第三季度的研发开支为6600万美元，2023年同期为5880万美元。这一增长主要是由于许可及合作协议的预付款和里程碑费用增加，部分被持续的资源优化和效率提升而带来的临床研究费用和人员成本下降所抵销。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.